TITLE

2008 - Rosuvastatin prevented major cardiovascular events in persons with elevated C-reactive protein

AUTHOR(S)
Campbell-Scherer, Denise L.; Montori, Victor M.
PUB. DATE
January 2009
SOURCE
ACP Journal Club;1/1/2009, Vol. 150 Issue 1, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that in healthy older adults with elevated C-reactive protein levels who do not have hyperlipidemia, rosuvastatin reduced stroke and myocardial infarction. The randomized placebo-controlled trial titled "Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin," supports the possibility that high-sensitivity C-reactive protein could be helpful in selecting candidates for higher-dose statins.
ACCESSION #
36506317

 

Related Articles

  • Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. Ridker, Paul M.; Rifai, Nader; Clearfield, Michael; Downs, John R.; Weis, Stephen E.; Miles, J. Shawn; Gotto, Antonio M. // New England Journal of Medicine;06/28/2001, Vol. 344 Issue 26, p1959 

    Background: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent...

  • Is Jupiter Also a God of Primary Prevention? Accad, Michel; Fred, Herbert L. // Texas Heart Institute Journal;2010, Vol. 37 Issue 1, p6 

    The article focuses on the clinical research trial named Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The trial included 17,802 healthy middle-aged men and women who did not have hyperlipidemia but did have elevated level of...

  • Statin Drugs Can Reduce Heart Attacks.  // USA Today Magazine;Oct2001, Vol. 130 Issue 2677, p4 

    Focuses on a study which examined the role of statin drugs in reducing risk of heart attacks. Role of the drugs in lowering levels of C-reactive protein; Methodology.

  • A simple test. Comarow, Avery // U.S. News & World Report;5/6/2002, Vol. 132 Issue 15, p55 

    Reports that a blood test for a substance called C-reactive protein, or CRP, is an effective way to identify people at risk of a heart attack or stroke. Comment that sixteen studies have demonstrated the value of CRP testing, according to cardiologist Paul Ridker; Outlook for the use of statin...

  • Cholesterol-lowering drugs are just as effective at preventing heart problems in men and women who have already had a heart attack or stroke, according to a new review of the evidence.  // MondayMorning;7/2/2012, Vol. 20 Issue 26, p1 

    The article discusses a study, conducted by researcher Jose Gutierrez and colleagues, which found that stanins are effective in preventing heart problems in patients already having a stroke. Researchers studied various trials in which patients at risk of a second heart attack or stroke were...

  • STATlN THERAPY, C-REACTIVE PROTEIN LEVELS, AND RISK OF FUTURE ADVERSE CORONARY EVENTS: A PROSPECTIVE OBSERVATIONAL STUDY. Russell, C. J. H.; Exley, A. R.; Buckenham, S. J.; Jarrett, E. J.; Marshall, C. J.; Charman, S. C.; Bennett, M. R.; Shapiro, L.; Ritchie, A. J. // Heart;May2004 Supplement 3, Vol. 90, pA13 

    This article presents a study on station therapy, AC-reactive protein levels, and risk of future adverse coronary events. Clinical trials of statin therapy report reductions in morbidity and mortality exceeding that predicted by the actual reduction in serum lipid achieved. These findings...

  • JUPITER: C-reactive Protein a Marker for CV Events?  // Clinical Oncology Alert;Jan2009 Pharmacology Watch, p1 

    The article reports on the findings of the JUPITER trial which showed that elevated high-sensitivity C-reactive protein (CRP) may help identify patients who will benefit from statin therapy. In the study, healthy men and women with normal cholesterol levels were given rosuvastatin and placebo....

  • JUPITER: C-reactive Protein a Marker for CV Events? Elliott, William T. // Travel Medicine Advisor;Jan2009 Supplement, p1 

    The article reports on the findings of the JUPITER trial regarding the role of elevated high-sensitivity C-reative protein (CRP) in identifying healthy patients with normal cholesterol levels who will benefit from statin therapy. In the trial, researchers randomized some 18,000 healthy men and...

  • C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. Bikdeli, Behnood // Cardiovascular Drugs & Therapy;Dec2011, Vol. 25 Issue 6, p545 

    The association between C-reactive protein (CRP) and cardiovascular disease has been under investigation for more than sixty years. Lately, findings from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial opened a new frontier:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics